Operating CF
$1.78B
Capex
−$353.10M
Free Cash Flow
$1.43B
FCF Margin
+80.2%
Cash flow waterfall for DexCom (DXCM) — TTM through Q1 2026
Free cash flow: $1.43B
Note: Other Investing is large — driven mainly by purchases or sales of investments.
Cash flow breakdown for DexCom (DXCM) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | $1.78B | $1.78B |
| Capital Expenditure | −$353.10M | $1.43B |
| Free Cash Flow | $1.43B | $1.43B |
| Other Investing | $490.40M | $1.92B |
| Share Buybacks | −$535.80M | $1.38B |
| Other Financing & FX | −$1.17B | $212.30M |
| Net Cash Increase | $212.30M | $212.30M |
- Operating Cash Flow$1.78B
- Capital Expenditure−$353.10M
- Free Cash Flow$1.43B
- Other Investing$490.40M
- Share Buybacks−$535.80M
- Other Financing & FX−$1.17B
- Net Cash Increase$212.30M
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
DexCom (DXCM) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement